Nanoform Finland Plc | Inside Information | May 20, 2025 at 07:45:00 EEST
Helsinki, Finland – Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it has signed a letter of intent to establish, in collaboration with two healthcare specialist investors, BRAFMed Ltd, a new company to progress the clinical development and outlicensing of Nanoencorafenib, a bioequivalent patient-centric nanoformulation of encorafenib used for the treatment of certain melanoma and other cancers.
Encorafenib, sold under the brand name Braftovi®, a registered trademark of Pfizer, is an orally administered anti-cancer medication. Nanoform has developed a prototype nanoformulation (named Nanoencorafenib) ready for bioequivalence studies. If successful, the nanoformed product would offer greatly improved dosing over that of the marketed formulation, which requires a dosing regimen of up to six 75mg capsules taken daily. Clinical development and manufacturing of nanoformed drug substance for evaluation will take place at Nanoform’s state of the art development and manufacturing facility in Helsinki.
"Nanoform’s performance-enhancing technologies play a significant part in the development of new and improved medicines, and we are proud today to announce the intention to partner for the clinical development and commercialization of Nanoencorafenib, which is one of our innovative development initiatives,” said Prof. Edward Hæggström, CEO of Nanoform. “This collaboration underscores investor confidence in our technology and we are pleased to enter this collaboration with these highly experienced healthcare investors to drive this improved product forward."
Subject to closing of the definitive agreements, expected during 2Q 2025, Nanoform will continue to support development of Nanoencorafenib with its nanoforming services and will grant an exclusive license to BRAFMed Ltd for Nanoform’s intellectual property covering Nanoencorafenib. Under the agreement, BRAFMed Ltd will pay Nanoform service fees, low single million development milestones, and up-to-mid-single digit tiered %-royalty. The BRAFMed Ltd partners’ target is to ultimately outlicense Nanoencorafenib as an attractive patient-centric lifecycle management or value-added generic medicine opportunity.
At incorporation, BRAFMed Ltd is expected to be a wholly owned subsidiary of Nanoform, and the investors plan to invest an initial EUR 2-3 million and with an option to invest an additional EUR 1-2 million into BRAFMed Ltd, at a pre-money valuation of EUR 5 million. Following completion of the total investment, Nanoform’s fully diluted ownership in BRAFMed Ltd is expected to be 40-50%. The investment is expected to be sufficient to finance the clinical development of Nanoencorafenib up and until its commercialization.
The information in the company release is information that Nanoform is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on May 20, 2025, 07.45 EEST / 06.45 CEST.
For further information, please contact:
Dr. Edward Hæggström, CEO
Edward.haeggströn@nanoform.com
+358 (0)29 370 0150
M.Sc. Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 (0)7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 (0)73 856 42 65, certifiedadviser@carnegie.se. For more information, please visit www.nanoform.com.
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words “may”, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2024 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.